GV.PA Genomic Vision SA EURONEXT: Most active €0.0018 Feb 2026, watch liquidity

The GV.PA stock closed the EURONEXT session at €0.0018 on 04 Feb 2026 after heavy trading, making it one of Europe’s most active small caps today. Volume finished at 38,489,238 shares, more than double the 14,217,513 average, driving a 5.88% intraday rise from the previous close. Investors are watching liquidity and valuation closely because market cap stands at only €693,191.00 while the 50-day average price is €0.004844 and the 200-day average is €0.013997.

GV.PA stock: Market snapshot and trading flow

Genomic Vision SA (GV.PA) traded between €0.0015 and €0.0020 intraday, closing at €0.0018 on EURONEXT. Volume at 38,489,238 shares was 2.71x the average, signalling speculative or news-driven flows rather than steady accumulation. High relative volume with a market cap of €693,191.00 highlights extreme liquidity risk for larger positions.

GV.PA stock: Financials and valuation metrics

GV.PA reports trailing EPS of -0.11 and a negative PE ratio near -0.02, reflecting persistent losses. Price-to-sales is 0.47 and enterprise value to sales is 1.60, while cash per share is 0.00557 and current ratio is 0.91, showing tight short-term liquidity. These metrics imply a distressed small-cap biotech profile with high research spend and limited operating cash flow.

GV.PA stock: Why the volume spike matters

The volume surge to 38.49M shares suggests short-term traders and repositioning by micro-cap investors dominated today’s action. With shares outstanding at 385,105,984 and free float likely limited, even modest buy or sell orders move price widely. For traders, the high relative volume increases intraday volatility but worsens execution risk for large orders.

GV.PA stock: Meyka grade, technicals and outlook

Meyka AI rates GV.PA with a score out of 100: 58.59 — Grade C+ with a HOLD suggestion. This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key metrics, forecasts, analyst consensus, and fundamental signals. Technicals remain weak versus the 50-day average (€0.004844) and 200-day average (€0.013997), so short-term momentum is driven by volume spikes not trend strength.

GV.PA stock: Risks, catalysts and sector context

Key risks are cash burn, limited working capital and low liquidity; current ratio is 0.91 and interest coverage is negative near -8.98, underscoring funding pressure. Potential catalysts include partnership updates (existing alliance with Quest Diagnostics) and product adoption of the FiberVision platform in diagnostics. In Healthcare diagnostics, sector moves can lift micro-cap peers, but GV.PA’s fundamentals require material operational progress to change valuation.

GV.PA stock: Forecasts, price targets and analyst view

Meyka AI’s forecast model projects a near-term reference target of €0.0040 and a 12-month scenario of €0.0100 compared with the current price of €0.0018. That implies an upside of 122.22% to the near-term target and 455.56% to the 12-month scenario, but forecasts are model-based projections and not guarantees. For coverage and related news see the latest market transcript summary source and our internal GV.PA page Meyka GV.PA page.

Final Thoughts

GV.PA stock closed the EURONEXT session at €0.0018 on 04 Feb 2026 after an outsized 38,489,238 share session, marking it among the most active European micro-caps today. Trading activity appears driven by short-term flows rather than fundamental upgrades; revenue-per-share is low at 0.01 and EPS remains negative at -0.11, limiting near-term valuation support. Meyka AI rates GV.PA 58.59/100 (C+, HOLD), reflecting weak liquidity, negative profitability and modest sector tailwinds. Our model projects €0.0040 near term (implied +122.22% vs €0.0018) and €0.0100 at 12 months (implied +455.56%), but these are scenario outcomes not guarantees. Investors seeking exposure should weigh extreme volatility, tight free float and funding risk against the upside scenarios from product adoption or corporate deals. Meyka AI provides this as data-driven market analysis; this is not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.